THE MEDICAL NEWS

Laverock Therapeutics (‘Laverock’), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announces its in vivo programs spanning CAR-T and genetic medicine

Probiotic supplementation in very preterm infants is linked to lower rates of necrotizing enterocolitis and mortality, according to a nationwide Swedish study.

Early smartphone use is linked to a rise in eating disorder symptoms among adolescents, indicating potential mental health implications that require attention.

INTEGRA's automated solutions optimize CRISPR workflows, enhancing gene editing efficiency and accelerating the path to innovative therapeutic developments.

Mouser Electronics, Inc., an authorized global distributor with the widest selection of semiconductors and electronic components, is shipping a wide array of new products and solutions from the YAGEO Group, a leading global passive component manufacturer.

Atlas Antibodies has launched AtlasPlex™, a new ready-to-use multiplex immunohistochemistry kit. It lets researchers build their own 3- or 5-plex panels from more than 17,000 IHC-validated antibodies covering over 12,000 human genes.

Atlas Antibodies is 20 years old. The company is the original manufacturer of the antibodies used to map the human proteome in the Human Protein Atlas (HPA).

Atlas Antibodies has launched MolBoolean™, a new in situ proximity assay. It detects free protein A, free protein B, and the A–B complex together in fixed cells and tissue.

One in three breast cancer survivors will experience cognitive problems, which can include difficulties with attention, memory, processing speed and other aspects of thinking.